Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma: a real-life experience
Articles > Article · 2018
Authors: Nur SOYER, Pusem Patir, Ayse Uysal, Mustafa Duran, Hatice Demet Unal, İsabel Raika DURUSOY, Murat TOMBULOĞLU, Fahri ŞAHİN, Mahmut TÖBÜ, Filiz VURAL, Güray SAYDAM
TURKISH JOURNAL OF MEDICAL SCIENCES, Journal Indexed in SCI Expanded, International, 2018, vol 48, pp 777-785
DOI: 10.3906/sag-1712-160
Summary
Background/aim: In Turkey, lenalidomide plus dexamethasone (RD) has been used to treat relapsed/refractory multiple myeloma (RRMM) since 2010. This retrospective, single-center study evaluated the efficacy and tolerability of RD in patients with RRMM between October 2010 and June 2016.